Astellas Pharma Inc. has acquired Quethera, a gene therapy company headquartered in the UK, focused on developing novel treatments for ocular disorders, for as much as £85 million in upfront and contingent payments. Upon closing, Quethera will become a wholly owned subsidiary of Astellas.   Astellas gains Quethera’s ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells for the treatme...